百奥赛图-B午前涨超6% IDE034首例患者给药 触发500万美元里程碑款项

Core Viewpoint - The stock of Baiaoshaitu-B (02315) has risen over 6%, currently at 53.35 HKD, following the announcement of a significant milestone in its collaboration with IDEAYA regarding the ADC IDE034 [1] Group 1: Company Developments - IDEAYA has completed the first patient enrollment in the Phase I dose escalation/expansion clinical trial for the dual-target PTK7/B7H3 ADC IDE034 [1] - The first patient dosing will trigger a milestone payment of 5 million USD from IDEAYA to Baiaoshaitu [1] - IDE034 is a potentially first-in-class dual-target B7H3/PTK7 TOP1 ADC, developed by Baiaoshaitu and licensed to IDEAYA in July 2024 [1] Group 2: Regulatory and Clinical Progress - The project received FDA approval for clinical trials in December last year, marking a significant regulatory achievement [1] - The IND approval signifies an important milestone in the collaboration, laying the groundwork for the subsequent clinical development of IDE034 [1] - This development highlights Baiaoshaitu's technical strength in the discovery and development of dual-target ADCs [1]